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Asthma is characterized by airway inﬂammation. Inﬂammation is associated with oxidant
stress. Airway epithelial cells are shielded from this stress by a thin layer of lung lining
ﬂuid (LLF) which contains an abundance of the antioxidant glutathione. LLF glutathione
metabolism is regulated by γ-glutamyl transferase (GGT). Loss of LLF GGT activity in the
mutant GGTenu1 mouse causes an increase in baseline LLF glutathione content which is
magniﬁed in an IL-13 model of allergic airway inﬂammation and protective against asthma.
Normal mice are susceptible to asthma in this model but can be protected with acivicin, a
GGT inhibitor. GGT is a target to treat asthma but acivicin toxicity limits clinical use. GGsTop
is a novel GGT inhibitor. GGsTop inhibits LLF GGT activity only when delivered through the
airway. In the IL-13 model, mice treated with IL-13 and GGsTop exhibit a lung inﬂammatory
response similar to that of mice treated with IL-13 alone. But mice treated with IL-13 and
GGsTop show attenuation of methacholine-stimulated airway hyper-reactivity, inhibition of
Muc5ac and Muc5b gene induction, decreased airway epithelial cell mucous accumulation
and a fourfold increase in LLF glutathione content compared to mice treated with IL-13
alone. Mice treatedwith GGsTop alone are no different from that ofmice treatedwith saline
alone, and show no signs of toxicity. GGsTop could represent a valuable pharmacological
tool to inhibit LLF GGT activity in pulmonary disease models. The associated increase in
LLF glutathione can protect lung airway epithelial cells against oxidant injury associated
with inﬂammation in asthma.
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INTRODUCTION
The lung epithelial surface is bathed by a thin, continuous layer
of ﬂuid referred to as lung lining ﬂuid (LLF). Its function has
been described as a shield at the air–liquid interface to pro-
tect the lung epithelium from environmental stress (Cantin et al.,
1987). The LLF provides an aqueous medium for the exchange
of molecules within the surfactant system, a supportive milieu
for the alveolar macrophage, a protective surface for the alveo-
lar septum, and thin component of the blood-diffusion distance
(Bastacky et al., 1995). Among the small molecule antioxidants
present in LLF,glutathione (GSH)has received particular attention
because its concentration exceeds that of the blood by 100-fold and
its abundance exceeds that of LLF glutathione disulﬁde (GSSG;
Cantin et al., 1987). In addition, the lung overall utilizes more
glutathione than any other organ (Martensson et al., 1989). Cellu-
lar glutathione synthesis and extracellular export and metabolism
impact overall glutathione homeostasis (Lieberman et al., 1996;
Dalton et al., 2000; Shi et al., 2000). Metabolism of glutathione
is regulated by gamma-glutamyl transferase (EC 2.3.2.2, GGT)
and provides a cysteine source for cellular glutathione resynthe-
sis (Hanigan and Ricketts, 1993). GGT is present in the lung as
a soluble enzyme in association with surfactant phospholipids
and controls turnover of the extracellular pool of glutathione
in LLF (Joyce-Brady et al., 1994; Jean et al., 2002). The biologi-
cal role of the LLF glutathione pool and its metabolism by GGT
was revealed through our studies in a genetic mouse model of
GGT deﬁciency, the GGTenu1 mutant mouse (Harding et al., 1997;
Jean et al., 1999, 2002; Lowry et al., 2008). In a IL-13-driven
model of experimental allergic asthma, GGTenu1 mutant mice
were protected against asthma, despite the presence of cellular
glutathione deﬁciency and oxidant stress in lung airway epithe-
lial cells (Jean et al., 2002; Lowry et al., 2008). IL-13 is a well
described pro-inﬂammatory cytokine that drives inﬂammation
in a mouse model of experimental asthma (Grunig et al., 1998;
Zhu et al., 1999). This cytokine-driven model evokes a similar
degree of inﬂammatory cell inﬁltration into the lungs of normal
mice and GGTenu1 mutant mice, thereby allowing study of their
lung response to inﬂammation (Lowry et al., 2008; Joyce-Brady
et al., 2012). We found that the GGT deﬁcient GGTenu1 mouse
was protected against asthma in this model by an increased size
of the extracellular LLF glutathione pool which buffered oxidant
species derived from inﬂammatory cells, and preserved airway
epithelial cell barrier function. In turn, induction of mucin gene
expression, mucous production and airway hyperreactivity were
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dramatically decreased in GGTenu1 mutant mice. Control mice
did develop asthma but could be protected against this by inac-
tivating their LLF GGT activity pharmacologically with acivicin,
an irreversible GGT enzyme inhibitor. These data revived inter-
est in the extracellular LLF glutathione pool and suggested that
GGT activity in LLF is a novel target to treat asthma (Lowry
et al., 2008; Joyce-Brady et al., 2009; Joyce-Brady and Hiratake,
2011).
Human pharmacotherapy with acivicin, however, is limited by
neurotoxicity and cytotoxicity caused by an extended inhibitory
activity against a number of other glutamine-dependent biosyn-
thetic enzymes (Hidalgo et al., 1998; Joyce-Brady and Hiratake,
2011). These limitations led to the rational design of novel class
of glutamate analogous γ-phosphono diesters as mechanism-
based inhibitors of GGT. These compounds are based on stable
analogs of the enzyme transition state and inhibit GGT activ-
ity with greater potency and speciﬁcity than acivicin (Han et al.,
2006, 2007; Joyce-Brady and Hiratake, 2011). We focused on
the lead compound from this class, now commercially available
as GGsTop, for three reasons: lack of toxicity in vivo, phys-
ical stability in vitro and extended inhibitory activity against
mammalian as well as bacterial GGT (Han et al., 2006, 2007).
We hypothesized that GGsTop could attenuate asthma in the
IL-13-driven model of allergic airway inﬂammation in mice
and represent a valuable alternative to acivicin as a clinical
therapeutic.
MATERIALS AND METHODS
INHIBITORY ACTIVITY OF GGsTop IN VIVO
A crystalline form of GGsTop was synthesized according to
the previous report (Han et al., 2007). GGsTop is freely sol-
uble in distilled water so a 10 mM stock solution was pre-
pared, stored at −20◦C and aliquoted for experiments. The
compound is now available commercially as GGsTopTM from
Wako Pure Chemical Industries, Ltd. (Osaka, Japan). In pre-
liminary studies, GGsTop was assessed for its ability to inhibit
GGT enzyme activity in vivo in mouse lung and serum at
0.5 mg/kg and 5 mg/kg. GGsTop was delivered via the peri-
toneum or through the trachea in a volume of 100 μL. GGT
activity was assessed 2 h and 24 h afterward after delivery in
bronchoalveolar lavage ﬂuid and serum. Controls received phos-
phate buffered saline (PBS). GGT enzyme activity was assessed
at room temperature using a standardmethod with γ-glutamyl-p-
nitroanilide as substrate (Hughey andCurthoys,1976; Joyce-Brady
et al., 1994). Data are expressed as a percentage of the control
group.
MOUSE MODEL OF IL-13-DRIVEN EXPERIMENTAL ALLERGIC ASTHMA
C57BL/6 mice were housed in the Laboratory and Animal Science
Center at Boston University School of Medicine under guidelines
approved by the local Institutional Animal Care and Utilization
Committee in protocol number AN-14284. Animals were fed
Purina mouse chow and allowed access to water ad libitum. In
each experiment, two groups of 6–8 mice were pre-dosed with
saline or GGsTop dissolved in PBS via the trachea on day 0.
Thereafter 3–4 mice were treated every 24 h for three succes-
sive days with either saline alone (control), saline with IL-13,
saline with GGsTop, or saline with IL-13 and GGsTop. The IL-
13 dose was ﬁve micrograms and the GGsTop was 0.5 mg/kg.
On the ﬁnal day, airway resistance (Rn) was measured using an
intratracheal catheter on a Scireq ﬂexivent apparatus (SCIREQ,
Montreal, PQ, Canada) under appropriate anesthesia with pen-
tobarbital. The tidal volume was 6–7 ml/kg, the positive-end
expiratory pressurewas 3 cmH2O,and the respiratory ratewas 150
breaths/min. Basline airway resistance was measured after deliv-
ery of nebulized saline followed by increasing doses of nebulized
methacholine Mch (5, 15, and 25 mg/ml). Data were normal-
ized to the baseline level. Thereafter, lungs were either frozen to
isolate RNA, inﬂation-ﬁxed with paraformaldehyde for histology
or lavaged to collect bronchoalveolar lavage ﬂuid (Lowry et al.,
2008).
RNA ANALYSIS
Total RNA was isolated from frozen lung tissue, quantiﬁed
by spectrophotometry and assayed for messenger RNA tran-
script abundance using standard real time PCR methodology as
described (Lowry et al., 2008). The messenger RNA included two
mucin genes, Muc5ac and Muc5b (Lowry et al., 2008) and the
cytokine IL33 (Moffatt et al., 2010).
HISTOLOGY AND CYTOLOGY
Standard techniques were used to ﬁx lung tissue in 4%
paraformaldehyde and to embed in parafﬁn. Sections were stained
with periodic acid-Schiff (PAS) stain as described (Lowry et al.,
2008). Cells in bronchoalveolar lavage were collected with low
speed centrifugation, transferred to glass slides, stained with
Giemsa, and visualized under light microscopy.
BRONCHOALVEOLAR LAVAGE
Mouse lungs were inﬂated with 500 μL of PBS and centrifuged
to sediment cells. The cell pellet was used to prepared cytospin
preps and stained with Geimsa. The cell-free supernatant was
combined with a sulfhydryl preserving solution and assayed for
glutathione content by HPLC and normalized based on the urea
dilution method as described previously (Jean et al., 2002; Lowry
et al., 2008). Total glutathione content is reported.
STATISTICS
Nominal data are presented as means with SE and analyzed by
ANOVA and Dunnet’s or Bennett’s post hoc test as indicated. P
values<0.05 were considered signiﬁcant.
RESULTS
LUNG LINING FLUID GGT ACTIVITY IS INHIBITED BY GGsTop ONLY
WITH INHALATION
Lung lining ﬂuid GGT activity was not inhibited with GGsTop
delivery thru the peritoneum at the 0.5 mg/kg dose (Figure 1A,
n = 2) nor at the 5 mg/kg dose (same pattern, data not shown).
This route did inhibit GGT activity in the blood (Figure 1B). The
inhibition at 2 h was dose dependent with serum activity decreas-
ing to 60% of control with 0.5 mg/kg (p < 0.05, n = 3) and
90% of control with 5 mg/kg (p < 0.05, n = 3). By 24 h there
was a regain of serum GGT activity to 100% of control with the
0.5 km/kg dose (n = 2) and 67% of control with the 5 mg/kg dose
(n = 2).
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FIGURE 1 | Inhibition of lung lining fluid (LLF) GGT activity with delivery
of GGsTop via the trachea, but not the peritoneum. GGsTop was delivered
thru the trachea and the peritoneum at doses of 0.5 mg/kg and 5 mg/kg. GGT
activity was assessed in broncho-alveolar lavage ﬂuid (A,C) and serum (B,D)
as described in “Materials and Methods.” Data are expressed as percentage
versus the control group. Signiﬁcant differences at p < 0.05 are denoted by
asterisks (n = 3). The data in 1A and those in 1B at 24 h are averages from
n = 2 replicates.
Two hours after GGsTop was delivered via the trachea, the
0.5 mg/kg dose and the 5 mg/kg dose each inhibited GGT
enzyme activity in LLF to 40% of control (p < 0.05, n = 3,
Figure 1C). Intratracheal delivery of GGsTop (0.5 mg/kg) also
inhibited serum GGT activity to 20% of control at 2 h (p < 0.05,
n = 3) and this decrease was still evident 24 h later (30% of
control, p < 0.05, n = 3, Figure 1D). The 0.5 mg/kg dose
was used for the IL-13 experiments and delivered through the
trachea.
GGsTop ATTENUATES IL-13 INDUCED AIRWAY HYPER-REACTIVITY
Treatment of mouse lung with IL-13 caused a signiﬁcant, and
dose dependent increase in relative airway resistance following
methacholine challenge compared to saline treated control mice
(Figure 2). This pattern was attenuated at eachmethacholine dose
when GGsTop was added to IL-13. The effect was signiﬁcant at the
highest dose (p< 0.0001, n = 9). Administration of GGsTop alone
did not alter the airway resistance parameter versus the control
group.
GGsTop AUGMENTS TOTAL GLUTATHIONE IN LUNG LINING FLUID IN
THE PRESENCE OF IL-13
Total gutathione was measured in LLF at the end of the IL-13
experiment. In the absence of IL-13, GGsTop did not change LLF
glutathione from that of the saline control (Figure 3A). IL-13
treatment itself did not change LLF glutathione either. However,
treatment with IL-13 and GGsTop increased LLF glutathione by
almost fourfold (p < 0.05, n = 3).
IL-13 DRIVEN INFLAMMATION IS UNAFFECTED BY GGsTop, BUT
INDUCTION OF MUCOUS EXPRESSION IS ATTENUATED
Compared to control lung, exposure to IL-13 induced the level of
lung mRNA transcript expression for IL-33 by sixfold (Figure 3B)
and recruited eosinophils to the lung in the absence (Figure 3C)
and presence (Figure 3D) of GGsTop.
IL-13 treatment induced the lung level of messenger RNA tran-
script expression for Muc5ac 28-fold (p< 0.05, n = 3, Figure 4A)
and Muc5b sixfold (p < 0.05, n = 3, Figure 4B) versus con-
trol mice treated with saline alone. Compared to PBS treated lung
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FIGURE 2 | GGsTop attenuates airway hyper-reactivity induced by
IL-13. Induction of airway hyperreactivity was measured by assaying airway
resistance during graded methacholine challenge as described in
“Materials and Methods.” Asterisks denote signiﬁcant increase in airway
resistance over baseline in each group (p < 0.05). IL-13 treatment
increased airway resistance at each methacholine dose compared to saline
control (n = 9/methacholine dose). Administration of GGsTop alone did not
alter the airway resistance parameter versus the control group. Addition of
GGsTop to IL-13, however, attenuated airway resistance at each dose of
methacholine with a signiﬁcant decrease at the highest dose
(n = 9/methacholine dose, p < 0.0005).
(Figure 4C), PAS stain of IL-13 treated lung showed a diffuse signal
formucous in airway epithelial cells (Figure 4E; Lowry et al.,2008).
When GGsTop was added to IL-13, induction of messenger RNA
transcript for Muc5ac was decreased sevenfold (Figure 4A) and
that of Muc5b twofold (Figure 4B) and PAS stained lung showed
only rare airway epithelial cells with a mucous signal (Figure 4F).
GGsTop treatment alone affected neither mucin gene expression
nor mucous production (Figures 4A,B,D).
DISCUSSION
Oxidant stress is believed to be important in asthma pathogene-
sis (Rahman et al., 2006). An inverse relationship has been noted
previously in humans between the level of the antioxidant glu-
tathione in LLF and airway hyperreactivity. That is a higher level
of lung lining ﬂuid glutathione is associated with lesser degree
of airway hyperreactivity (Smith et al., 1993). The antioxidant
glutathione is found in abundance in the lining ﬂuid and pro-
tects the surface of the lung against oxidant stress (Cantin et al.,
1987). LLF glutathione is metabolized by the enzyme GGT, which
we showed is also present in lung lining ﬂuid (Joyce-Brady et al.,
1994). GGT expression in inducible LLF with inhalation of oxi-
dant gas (Takahashi et al., 1997) and in many different cells in
the lung during injury, including neutrophils, (Corti et al., 2012),
bronchiolar Clara cells (Takahashi et al., 1997), and type 2 epithe-
lial cells (van Klaveren et al., 1997). GGT-mediated glutathione
metabolism provides cells with cysteine at the expense of the
lung lining ﬂuid glutathione pool. Interestingly, genetic deﬁciency
of GGT in GGTenu1 mice induced an asthma-resistant pheno-
type in an IL-13-driven model of allergic airway hyperreactivity.
Lung lining ﬂuid glutathione content was augmented nearly 10-
fold over that of normal mice at baseline, when GGT deﬁcient
GGTenu1 mice were exposed to this model of cytokine-driven
inﬂammation. This enhanced antioxidant availability buffered
inﬂammation-associated oxidant stress and attenuated airway
epithelial cell EGF-receptor activation, induction of mucous
hypersecretion and airway hyper-reactivity in GGTenu1 mice.
Protection against asthma was conferred on normal mice by
pharmacologic inhibition of LLF GGT with acivicin. Our data
identiﬁed GGT as a target to treat asthma. We proposed this as a
novel asthma treatment strategy to complement current asthma
therapeutics which target inﬂammation (Lowry et al., 2008).
Our studies in the GGTenu1 mouse also demonstrated the value
of this animal model in deﬁning a biologic role for extracel-
lular pools of glutathione in combating oxidant stress derived
from inﬂammation. These observations can be translated into
normal mice by augmenting their LLF glutathione thru inhibi-
tion of GGT enzyme activity (Joyce-Brady and Hiratake, 2011).
In our original paper we successfully used acivicin to inhibit
GGT activity. This inhibition is irreversible but certain adverse
effects are already known to limit clinical acivicin use. It is non-
speciﬁc and inhibits other glutamine amidotransferases as well
as GGT (Joyce-Brady and Hiratake, 2011). It is also neurotoxic
in vivo as shown in previous human clinical trials as a cancer
therapeutic (Olver et al., 1998). GGsTop was actually rationally
designed to eliminate both of these adverse drug interactions. Like
acivicin, GGsTop is an irreversible inhibitor of GGT but is specif-
ically designed for added potency and GGT selectivity (Han et al.,
2006, 2007). Thus far GGsTop has exhibited no reported toxic-
ity in vivo and has been utilized in a renal ischemia/reperfusion
injury model in rats (Yamamoto et al., 2011). We did not observe
any gross toxicity in normal mice with the doses used in this
study.
Interestingly, systemic delivery of GGsTop at a single time
inhibited serum GGT activity in a dose dependent manner and
to a greater degree than airway delivery. But GGT activity reap-
peared within 24 h suggesting a more rapid clearance of GGsTop
from the blood and replacement with active enzyme. GGT activ-
ity in LLF was totally unaffected by systemic delivery of GGsTop.
Instead, GGsTop had to be delivered thru the airway to inhibit
this pool of GGT activity within the lung. This was similar to our
previous experience with acivicin (Lowry et al., 2008). The basis
for this is not fully known. It is possible that ﬁrst pass metabolism
and clearance through the liver limits drug availability in the lung.
Alternatively, both GGsTop and acivicin are hydrophilic and nei-
ther appears to penetrate the lung from the blood very efﬁciently.
Several derivatives of GGsTop have been described and hydropho-
bicity may be related to ability to penetrate into the lung from
the blood stream and inhibit LLG GGT activity (Han et al., 2006,
2007; Joyce-Brady and Hiratake, 2011). Nonetheless, airway deliv-
ery of GGsTop was effective in inhibiting GGT activity in LLF
and in serum as well. Inhibition of serum GGT activity lasted up
to 24 h after inhalation. Hence, there may be an advantage to
inhaled GGsTop in that the lung can function as a GGsTop reser-
voir for the slow delivery of drug to the periphery to maintain
inhibition of systemic GGT activity and augment plasma glu-
tathione content and antioxidant defense which is known to be
depleted during the pathophysiological state of sepsis (Malmezat
et al., 2000).
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FIGURE 3 | (A) GGsTop augments LLF glutathione in the presence of
IL-13. Total Glutathione concentration (μM/ml) was measured in LLF at
the end of the IL-13 experiment as described in “Materials and
Methods” mice with the saline treated mice as control (0.4 μM/ml,
n = 3). The glutathione concentration was similar to that of control
after treatment with GGsTop (n = 3) and IL-13 (n = 3). It was
signiﬁcantly increased fourfold (1.6 μM/ml) in mice treated with GGsTop
along with IL-13 (***p < 0.01, n = 3). (B–D) The IL-13 proinﬂammatory
response is unaffected by GGsTop as IL-33 messenger RNA expression
(B), assessed by qRT-PCR in total RNA isolated from lung as described
in “Materials and Methods,” is induced sixfold by IL-13 treatment alone
(n = 3) and with GGsTop (n = 3), and an eosinophilic inﬁltrate
predominates with IL-13 alone (C) and with GGsTop (D) as described
by Lowry et al. (2008).
Lung lining ﬂuid GGT activity was inhibited equally well by
the two doses (0.5 or 5 mg/kg) of GGsTop used in our study
and we used the lower dose for all subsequent experiments. This
result may reﬂect the fact that the lung has much less GGT activity
overall compared to organs like the kidney or the pancreas even
though GGT activity in the LLF is concentrated sevenfold over
that of the lung as a whole (Joyce-Brady et al., 1994). Relative inhi-
bition of GGT activity in LLF was somewhat less than that of the
serum. The basis for this is not yet clear and further experiments
will be required to determine if the level of GGT inhibition in
the lung can be optimized further. Several derivates of GGsTop
are available and can be tested for differential inhibitory activ-
ity against LLF GGT (Han et al., 2007; Joyce-Brady and Hiratake,
2011).
The advantage of this IL-13 cytokine driven model of aller-
gic airway inﬂammation is in the similar levels of inﬂammatory
cells that are recruited to the lung. This permits one to focus on
lung airway epithelial cells and their response to the inﬂammatory
process (Joyce-Brady et al., 2012). Similarity of the inﬂammatory
response after IL-13 delivery to the lung in this study is sug-
gested by the comparable levels of induction of IL33 cytokine
messenger RNA and eosinophilic inﬁltrate in bronchoalveolar
lavage ﬂuid compared to untreated controls in the absence or
presence of GGsTop. However, that the lung responded differ-
ently after IL-13 delivery in the presence of GGsTop was shown in
three ways. Methacholine-stimulated airway hyperreactivity was
signiﬁcantly attenuated in mice treated with IL-13 and GGsTop,
whereas it was induced inmice treatedwith IL-13 alone. Induction
of mucin gene expression, assayed as messenger RNA expression
for Muc5ac and Muc5b, and mucous accumulation, visualized by
PAS staining, were signiﬁcantly attenuated in the lungs of mice
treated with IL-13 and GGsTop, but all were induced dramati-
cally in mice treated with IL-13 alone compared to control mice.
In all of our experiments using this IL-13 model, we hypoth-
esize that effective buffering of inﬂammation-derived reactive
oxygen species by the augmented glutathione pool in lung lining
www.frontiersin.org July 2014 | Volume 5 | Article 179 | 5
Tuzova et al. Treating asthma with inhaled GGsTop
FIGURE 4 | GGsTop attenuates mucous production induced by IL-13.
Compared to saline control, lung level of Muc5ac (A) messenger RNA
expression was not affected by GGsTop alone, but it was induced 28-fold
by IL-13 treatment (**n = 3, p < 0.001). When GGsTop was delivered with
IL-13, this level of messenger RNA induction was decreased sevenfold.
(B) Similarly, Muc5b messenger RNA was induced sixfold (B) by IL-13
treatment (**n = 3, p < 0.01) and this was decreased twofold when
GGsTop was delivered with IL-13. PAS stained lung (C–F) shows absence
of mucous in control (C) and GGsTop treated (D) lung, and a diffuse
mucous signal in airway epithelial cells after IL-13 treatment (E) but only
rare mucous signal in a few cells when GGsTop was added to IL-13 (F) as
described by Lowry et al. (2008).
ﬂuid protected airway epithelial cells from injury. LLF total glu-
tathione was augmented in the IL-13 treated GGTenu1 mouse
and in the normal mouse treated IL-13 and GGsTop, although
to a lesser degree. We believe this protection preserved airway
epithelial cell barrier function, prevented mucin gene induction
and attenuated development of airway hyperreactivity (Lowry
et al., 2008).
Other investigators have also proposed inhibiting GGT activity
as a treatment for human diseases besides asthma including can-
cer (Hanigan, 1998), cardiovascular disease (Emdin et al., 2005),
and cis-platinum-induced nephrotoxicity (Hanigan et al., 2001).
However, augmentation of glutathione availability was not the
proposed mechanism of action. Rather, it was decreased pro-
duction of a pro-oxidant glutathione metabolite Cys-Gly (Emdin
et al., 2005) or a toxic GGT-dependent cis-platinum-glutathione
conjugate (Townsend and Hanigan, 2002; Townsend et al., 2003).
Hanigan has even developed a novel alternative, non-toxic, and
non-competitive but reversible GGT inhibitor that could also
be used clinically to replace the toxicity of acivicin (King et al.,
2009). Nonetheless, GGsTop, a mechanism-based and irreversible
inhibitor of GGT, has been shown to be a non-toxic alternative
to acivicin in a recent study where it was used to inhibit GGT
activity and attenuate injury in a rat kidney ischemia/reperfusion
model (Yamamoto et al., 2011). Together these studies all sup-
port the use of novel GGT inhibitors as potential therapeutics
in GGT-dependent diseases. In addition, our ﬁndings may be
relevant for other lung diseases that involve inﬂammation and
perturb the extracellular LLF glutathione pool such as cystic ﬁbro-
sis, adult respiratory distress syndrome, and chronic obstructive
pulmonary disease (Cantin and Begin, 1991; Hull et al., 1997).
Our strategy to inhibit lining ﬂuid GGT activity is centered on the
augmentation of antioxidant defense by increasing glutathione
availability in the lung lining ﬂuid, thereby preserving the barrier
role of the lung epithelium and normal lung function. GGsTop
and its derivatives provide a new avenue for study toward that
goal.
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